BRIEF-Ascletis Pharma Inc Updates On ASC47

Reuters
18 Dec 2024
BRIEF-Ascletis Pharma Inc Updates On ASC47

Dec 18 (Reuters) - Ascletis Pharma Inc 1672.HK:

  • ASC47 IN COMBINATION WITH SEMAGLUTIDE DEMONSTRATED SUPERIOR WEIGHT LOSS TO SEMAGLUTIDE MONOTHERAPY IN A PRECLINICAL MODEL

Further company coverage: 1672.HK

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10